Abstract
The juvenile visceral steatosis (JVS) mouse, a murine model of systemic carnitine deficiency (SCD), causes disorder of fatty acid oxidation and develops cardiac hypertrophy with lipid accumulation. We investigated the effect of fenofibrate, a PPARalpha agonist, in addition to carnitine supplementation on the hypertrophied heart in JVS mice. JVS mice were fed a normal chow, 0.1% carnitine/kg containing chow (CA), or 0.1%carnitine/kg and 0.2% fenofibrate/kg containing chow (CA + FE) from 4 weeks of age. At 8 weeks, the ventricular hypertrophy in JVS mice was more attenuated by CA + FE than by CA alone. CA + FE normalized the content of myocardial ATP and triglycerides to control levels, and prevented the deterioration of left ventricular function. Combined therapy with PPARalpha agonist and carnitine supplementation may be beneficial in treating the cardiomyopathy due to SCD. [Display omitted]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.